Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234454 · ClinicalTrials.gov registry record · NA
Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT01234454 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 34 participants.
The verdict
NCT01234454, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
The general aim is to compare the effects of typical and atypical antipsychotic medication on brain structure and function. A parallel group treatment trial will be utilized to compare the effects of the typical antipsychotic thiothixene versus the atypical antipsychotics risperidone (RIS) and olanzapine (OLZ) on brain structure and function in schizophrenia in an effort to determine the neuroanatomic basis for cognitive pathology in schizophrenia and its amelioration by atypical antipsychotic drugs.
Interventions
- DRUG Risperidone
- DRUG Olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2002-01 |
| Est. Completion | 2007-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01234454
The ClinicalTrials.gov registry entry for NCT01234454 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risperidone is the first listed.
NCT01234454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01234454 about?
NCT01234454 is a clinical study titled "Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI". The general aim is to compare the effects of typical and atypical antipsychotic medication on brain structure and function. A parallel group treatment trial will be utilized to compare the effects of the typical antipsychotic thiothixene versus the atypical antipsychotics risperidone (RIS) and olanz...
What is the current status of trial NCT01234454?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2002-01. Estimated completion is 2007-12.
What interventions are being tested in trial NCT01234454?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG).
Who is sponsoring clinical trial NCT01234454?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.